CD8A and neoplasm: Preliminary studies have demonstrated that a subset of patients, particularly those with HPV-positive tumors, high tumor mutational burden (TMB), or high infiltration of intratumoral CD3+CD8+ T cells, may exhibit a favorable response to ICI therapy [33].